SCHEDULE: Frazier Life Sciences Discloses Valneva SE Stake

Frazier Life Sciences entities collectively report beneficial ownership of 3.6% of Valneva SE's ordinary shares as of May 5, 2026.

Summary

• Frazier Life Sciences Public Fund, L.P. and affiliated entities have filed a Schedule 13G, indicating their beneficial ownership of Valneva SE's ordinary shares.
• The total beneficial ownership reported is 6,879,516 shares, representing 3.6% of the company's outstanding ordinary shares as of May 5, 2026.
• This ownership stake is based on 189,771,237 ordinary shares outstanding, as per Valneva SE's press release on April 30, 2026.
• The filing details the ownership structure across several Frazier Life Sciences entities, including L.P. and L.L.C. structures.
• Certain warrants held by the Reporting Persons are excluded from the reported beneficial ownership figures due to beneficial ownership limitations (9.99%).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it is a standard disclosure of beneficial ownership and does not provide new operational or financial information about Valneva SE.

Positives

• Significant stake held by a specialized life sciences investment firm, potentially indicating confidence in Valneva SE's prospects.
• The filing is a routine disclosure for significant shareholders, providing transparency to the market.

Negatives

• The filing does not contain financial performance data or strategic updates from Valneva SE itself, only ownership information.
• The beneficial ownership is subject to limitations on warrants, meaning the actual potential ownership could be higher but is capped.

Risks

• The beneficial ownership is subject to a 9.99% limitation for warrants, meaning that if exercising these warrants would cause ownership to exceed this threshold, they cannot be exercised.
• The filing does not provide specific details on the strategic intent behind this ownership stake.

Future Outlook

The filing does not contain forward-looking statements or guidance from Valneva SE. It only reports current ownership stakes.

Industry Context

StockSavvy.ai notes that significant stakes held by specialized life sciences investment firms like Frazier Life Sciences often signal conviction in a company's technology, pipeline, or market position within the biotechnology and pharmaceutical sectors.

Stakeholder Impact

• Shareholders: Increased transparency regarding a significant institutional investor's holdings.
• Management of Valneva SE: Awareness of a substantial shareholder's position.
• Potential Investors: Information that may influence investment decisions based on institutional backing.

Next Steps

• Continued monitoring of Valneva SE's operational and financial performance by Frazier Life Sciences.
• Potential future filings if ownership levels change significantly.

Key Dates

Keywords

Valneva SE, Schedule 13G, Frazier Life Sciences, Beneficial Ownership, Ordinary Shares, American Depositary Shares, Investment Fund, Life Sciences